email article
Treatment with an oncolytic immunovirotherapy alone or with radiation appeared safe and effective in a phase I study of children and adolescents with heavily pretreated high-grade glioma.
Eleven of 12 patients with progressive or recurrent supratentorial high-grade gliomas achieved radiographic, neuropathological, or clinical responses following treatment with G207, a genetically engineered herpes simplex virus (HSV) delivered intratumorally via catheter, Gregory Friedman, MD, of the University of Alabama at Birmingham, reported at the American Association for Cancer Research virtual meeting.
The treatment was associated with few toxicities, and the median overall survival (OS) reached 12.2 months (95% CI 8.0-16.4), which compares favorably to an established median OS of 5.6 months in the recurrent setting. Four of the 12 patients (36%) have survived beyond 18 months, exceeding the typical life expectancy for newly diagnosed cases.
Unusual treatment shows promise for kids with brain tumours ctvnews.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ctvnews.ca Daily Mail and Mail on Sunday newspapers.
The study used genetically modified herpes virus to treat gliomas, which account for 8% to 10% of childhood brain tumors and often return after surgery, chemo or radiation.
UAB research: Modified herpes virus shows promise in treating pediatric brain tumors wsfa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wsfa.com Daily Mail and Mail on Sunday newspapers.
Unusual treatment shows promise for kids with brain tumors gjsentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gjsentinel.com Daily Mail and Mail on Sunday newspapers.